Can E-cadherin and CD34 be used as indicators of prognosis for hepatocellular carcinoma patients?
Li-Qun Wu1, Yun Lu, Hua-Jun Lu
1Department of Hepatobiliary Surgery, Affiliated Hospital of Medical College, Qingdao University, Qingdao, China. cloudylucn@163.com
Background:
The high postoperative recurrence of hepatocellular carcinoma (HCC) is a problem that would benefit from the identification of indicators of recurrence and prognosis. In the past few years, research has shown that E-cadherin and CD34 can be used as indicators of the invasion of malignant tumors. In the present study, we investigated the expression of E-cadherin and CD34 in HCC patients.
Methods:
Expression levels of E-cadherin and CD34 in 41 HCC samples were detected using two-step immunohistochemical methods and compared with clinical pathological parameters and survival rate.
Results:
The positive rates of E-cadherin and CD34 expression in 41 HCC cases were 48.78% and 100%, respectively. Expression of E-cadherin was significantly lower in patients with larger tumors, a high risk invasion and Edmondson classification III or IV (p<0.05). There was a significant relationship between CD34 expression and age and tumor invasiveness (p<0.05). There was no significant relationship between expression of CD34 and E-cadherin by Spearman statistical analysis (p>0.05). The survival rate in patients with negative expression of E-cadherin was significantly lower.
Conclusions:
The expression of CD34 cannot be used singly as a prognostic indicator for HCC patients. The co-expression of E-cadherin and CD34 cannot be used as a prognostic indicator for HCC patients. Clin Chem Lab Med 2008;46:1122-6.
